RxDoctor Payments Data

Omesh Verma, MD

Internal Medicine · Austin, TXNPI 1073561544

Payments from drug & device makers

$550,730in general payments, 2019–2025

Across 72 payments — averaging $7649.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$550K
  • Novo Nordisk$344
  • AstraZeneca$84
  • Bayer$71
  • Pfizer$55
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$45
  • plus $281 from 10 others
$91,439in research payments, 2019–2025

Across 3 payments — averaging $30,480 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$91K

What the payments were for

  • Food & beverage$87399%
  • Education$61%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$550,730 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$37,895
Medicare patients
129
Services billed
471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate98$127,941
EliquisApixaban81$78,544
TrulicityDulaglutide34$61,409
JardianceEmpagliflozin21$34,691
OzempicSemaglutide24$24,450
FarxigaDapagliflozin Propanediol27$22,348
MyrbetriqMirabegron31$19,435
JanumetSitagliptin Phos/Metformin Hcl15$16,862
Breo ElliptaFluticasone/Vilanterol24$14,922
Lantus SolostarInsulin Glargine,hum.Rec.Anlog101$13,545
Tresiba Flextouch U-100Insulin Degludec11$12,167
SymbicortBudesonide/Formoterol Fumarate38$10,254
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen204$7,481
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$6,927
Levemir FlexpenInsulin Detemir24$5,034

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$40$144,804113 claims
PfizerEliquis$55$78,54481 claims
Lilly USA, LLCTrulicity, Humulin 70-30$31$63,46545 claims
Boehringer IngelheimJardiance$30$34,69121 claims
AstraZenecaFarxiga, Symbicort$84$32,60265 claims
Novo NordiskOzempic$344$24,45024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →